FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296525> ?p ?o ?g. }

• W4367296525 abstract "<h3>Objective:</h3> To explore and document the patient experience of the prodrome phase of migraine. <h3>Background:</h3> Migraine can progress across four stages: prodrome, aura, headache, and postdrome. There is limited information on the percentage of people who experience the prodrome phase of migraine and the symptoms that characterize the experience. Prodrome may predict the onset of migraine headache hours in advance and can be key to help inform early treatment. <h3>Design/Methods:</h3> Eligible participants with clinician-confirmed diagnosis of migraine and at least one prodrome symptom were consented, screened, and participated in 60-minute concept elicitation interviews. The interview guide included open-ended questions to elicit spontaneous reports and specific probes about prodrome symptoms based on a clinician-established list. <h3>Results:</h3> Twenty interviews were completed and concept saturation was achieved. Participants reported 36 unique symptoms of prodrome. The most common (≥50.0%) were nausea, fatigue/tiredness, sensitivity to light, neck pain/stiffness, and dizziness/vertigo/light-headedness. Of the symptoms reported by at least four participants, neck pain/stiffness was rated most bothersome (8.9 out of 10) and sensitivity to light was rated most severe (8.5 out of 10). Fourteen (38.9%) symptoms were reported as occurring less than two hours before the start of migraine headache. Of the commonly reported symptoms, nausea (0.8 hours), sensitivity to light (1.0 hour), and dizziness/vertigo/lightheadedness (2.0 hours) occurred closest to headache onset; fatigue/tiredness (4.0 hours) and neck pain/stiffness (4.8 hours) were the most remote from headache onset. <h3>Conclusions:</h3> This study identified frequently reported prodrome symptoms, with participants reporting confidence that migraine headache would imminently follow within 1–6 hours. Characterizing the prodrome experience may improve the measurement of the burden of migraine and create opportunities to treat during the prodromal phase to prevent the onset of moderate or severe headaches. <b>Disclosure:</b> Jonathan Stokes has received personal compensation for serving as an employee of AbbVie. Jonathan Stokes has received stock or an ownership interest from AbbVie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NINDS. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from Veterans Administration. The institution of Dr. Lipton has received research support from NIH. Dr. Lipton has received publishing royalties from a publication relating to health care. The institution of Dr. Evans has received research support from AbbVie. The institution of Miss Hribal has received research support from AbbVie. The institution of Miss White has received research support from AbbVie. Dr. Keyloun has received personal compensation for serving as an employee of AbbVie. Dr. Keyloun has stock in AbbVie. Dr. Jariwala-Parikh has received personal compensation for serving as an employee of AbbVie. Dr. Jariwala-Parikh has stock in AbbVie. Pranav Gandhi has received personal compensation for serving as an employee of AbbVie. Pranav Gandhi has stock in AbbVie Inc. Dr. Dodick has received personal compensation for serving as an employee of Mayo Clinic. Dr. Dodick has received personal compensation for serving as an employee of Atria Health. Dr. Dodick has received personal compensation for serving as an employee of Thomas Jefferson University . Dr. Dodick has received personal compensation for serving as an employee of Norwegian University of Science and Technology. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Dodick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Allergan. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biopharm Communications. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inside Practice Australia. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Education Alliance. Dr. Dodick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Headache Cooperative of the Pacific . Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medica Communications. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJ Healthcare. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nocira. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance . Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapse Medical Communications. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vector Psychometrics. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as a Consultant for Ayya Biosciences. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as a Consultant for Theranica. Dr. Dodick has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Atria. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for WebMD. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Thomas Jefferson University. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medforce. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision HEOR. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for KingDevick Technologies. Dr. Dodick has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Precon Health. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Ontologics. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Matterhorn. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Axon Therapeutics. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Cephalgia Group. Dr. Dodick has stock in Healint. Dr. Dodick has stock in Theranica. Dr. Dodick has stock in Aural Analytics . Dr. Dodick has stock in Epien. Dr. Dodick has stock in Matterhorn. Dr. Dodick has stock in Ontologics. Dr. Dodick has stock in Precon Health. Dr. Dodick has stock in King Devick Technologies. Dr. Dodick has stock in Nocira. Dr. Dodick has stock in Exsano. Dr. Dodick has stock in Palion. Dr. Dodick has stock in AYYA Biosciences. Dr. Dodick has stock in Perfood. Dr. Dodick has stock in Cephalgia Group. Dr. Dodick has stock in Atria Health. Dr. Dodick has stock in Man and Science. The institution of Dr. Dodick has received research support from Department of Defense. The institution of Dr. Dodick has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Dodick has received research support from Henry Jackson Foundation. Dr. Dodick has received intellectual property interests from a discovery or technology relating to health care. Dr. Dodick has received intellectual property interests from a discovery or technology relating to health care. Dr. Dodick has received intellectual property interests from a discovery or technology relating to health care. Dr. Dodick has received publishing royalties from a publication relating to health care. Dr. Dodick has received publishing royalties from a publication relating to health care. Dr. Dodick has received publishing royalties from a publication relating to health care. Dr. Dodick has a non-compensated relationship as a Chair with American Brain Foundation that is relevant to AAN interests or activities. Dr. Dodick has a non-compensated relationship as a Committee member/Course Director with American Academy of Neurology that is relevant to AAN interests or activities. Dr. Dodick has a non-compensated relationship as a Chair/Immediate Past Chair with American Migraine Foundation that is relevant to AAN interests or activities. Dr. Dodick has a non-compensated relationship as a Chair Global Patient Advocacy Coalition with International Headache Society that is relevant to AAN interests or activities." @default.
• W4367296525 created "2023-04-29" @default.
• W4367296525 creator A5000448269 @default.
• W4367296525 creator A5009044802 @default.
• W4367296525 creator A5036025969 @default.
• W4367296525 creator A5054330051 @default.
• W4367296525 creator A5054933379 @default.
• W4367296525 creator A5057290642 @default.
• W4367296525 creator A5079132033 @default.
• W4367296525 creator A5084040192 @default.
• W4367296525 creator A5090254326 @default.
• W4367296525 date "2023-04-25" @default.
• W4367296525 modified "2023-09-29" @default.
• W4367296525 title "Characterizing the Patient Experience During the Prodrome Phase of Migraine: A Qualitative Study of Symptoms and Their Timing (P7-12.002)" @default.
• W4367296525 doi "https://doi.org/10.1212/wnl.0000000000202284" @default.
• W4367296525 hasPublicationYear "2023" @default.
• W4367296525 type Work @default.
• W4367296525 citedByCount "0" @default.
• W4367296525 crossrefType "proceedings-article" @default.
• W4367296525 hasAuthorship W4367296525A5000448269 @default.
• W4367296525 hasAuthorship W4367296525A5009044802 @default.
• W4367296525 hasAuthorship W4367296525A5036025969 @default.
• W4367296525 hasAuthorship W4367296525A5054330051 @default.
• W4367296525 hasAuthorship W4367296525A5054933379 @default.
• W4367296525 hasAuthorship W4367296525A5057290642 @default.
• W4367296525 hasAuthorship W4367296525A5079132033 @default.
• W4367296525 hasAuthorship W4367296525A5084040192 @default.
• W4367296525 hasAuthorship W4367296525A5090254326 @default.
• W4367296525 hasConcept C118552586 @default.
• W4367296525 hasConcept C15744967 @default.
• W4367296525 hasConcept C178790620 @default.
• W4367296525 hasConcept C185592680 @default.
• W4367296525 hasConcept C2778541695 @default.
• W4367296525 hasConcept C2779727114 @default.
• W4367296525 hasConcept C2780292510 @default.
• W4367296525 hasConcept C44280652 @default.
• W4367296525 hasConcept C71924100 @default.
• W4367296525 hasConceptScore W4367296525C118552586 @default.
• W4367296525 hasConceptScore W4367296525C15744967 @default.
• W4367296525 hasConceptScore W4367296525C178790620 @default.
• W4367296525 hasConceptScore W4367296525C185592680 @default.
• W4367296525 hasConceptScore W4367296525C2778541695 @default.
• W4367296525 hasConceptScore W4367296525C2779727114 @default.
• W4367296525 hasConceptScore W4367296525C2780292510 @default.
• W4367296525 hasConceptScore W4367296525C44280652 @default.
• W4367296525 hasConceptScore W4367296525C71924100 @default.
• W4367296525 hasLocation W43672965251 @default.
• W4367296525 hasOpenAccess W4367296525 @default.
• W4367296525 hasPrimaryLocation W43672965251 @default.
• W4367296525 hasRelatedWork W1985596252 @default.
• W4367296525 hasRelatedWork W2088834560 @default.
• W4367296525 hasRelatedWork W2090958871 @default.
• W4367296525 hasRelatedWork W2146621671 @default.
• W4367296525 hasRelatedWork W2236844763 @default.
• W4367296525 hasRelatedWork W2324678964 @default.
• W4367296525 hasRelatedWork W2748952813 @default.
• W4367296525 hasRelatedWork W2899084033 @default.
• W4367296525 hasRelatedWork W3026168621 @default.
• W4367296525 hasRelatedWork W3205052808 @default.
• W4367296525 isParatext "false" @default.
• W4367296525 isRetracted "false" @default.
• W4367296525 workType "article" @default.